We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+6.67%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$424M
AUM Growth
+$63.8M
Cap. Flow
+$75.3M
Cap. Flow %
17.76%
Top 10 Hldgs %
48.45%
Holding
91
New
14
Increased
28
Reduced
11
Closed
21

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$21.9M
2
ERAS icon
Erasca
ERAS
+$16.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$10.9M
4
URGN icon
UroGen Pharma
URGN
+$8.44M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$7.74M

Top Sells

Rank Stock Value
1
CATX icon
Perspective Therapeutics
CATX
+$7.96M
2
ALPN
Alpine Immune Sciences Inc
ALPN
+$7.89M
3
SLDB icon
Solid Biosciences
SLDB
+$7.63M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$5.98M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$5.83M

Sector Composition

Rank Sector Weight
1 Healthcare 95.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADCT icon
26
ADC Therapeutics
ADCT
$145M
$5.59M 1.32%
1,768,770
+1,267,548
+253% +$5.04M
BBOT
27
BridgeBio Oncology
BBOT
$701M
$5.11M 1.21%
500,000
– –
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
$5.03M 1.19%
100,023
-18,729
-16% -$1.35M
GOSS icon
29
Gossamer Bio
GOSS
$97.5M
$4.95M 1.17%
5,500,000
-630,268
-10% -$472K
TELA icon
30
TELA Bio
TELA
$29.1M
$4.7M 1.11%
1,000,000
+223,149
+29% +$1.18M
IRON icon
31
Disc Medicine
IRON
$2.85B
$4.56M 1.08%
+101,187
New +$3.44M
BIIB icon
32
Biogen
BIIB
$29.5B
$4.49M 1.06%
19,365
– –
VRNA
33
DELISTED
Verona Pharma
VRNA
$4.4M 1.04%
304,633
+167,919
+123% +$2.45M
GERN icon
34
Geron
GERN
$949M
$4.24M 1%
999,270
+749,270
+300% +$2.92M
BHVN icon
35
Biohaven
BHVN
$2.18B
$3.47M 0.82%
+100,000
New +$3.95M
LBPH
36
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$3.32M 0.78%
+122,849
New +$2.42M
PRAX icon
37
Praxis Precision Medicines
PRAX
$8.8B
$2.78M 0.66%
67,296
-123,260
-65% -$5.83M
GPCR icon
38
Structure Therapeutics
GPCR
$3.46B
$2.77M 0.65%
70,516
+60,516
+605% +$2.48M
BDSX icon
39
Biodesix
BDSX
$230M
$2.77M 0.65%
+90,448
New +$2.58M
MIRM icon
40
Mirum Pharmaceuticals
MIRM
$6.96B
$2.71M 0.64%
79,194
– –
SLDB icon
41
Solid Biosciences
SLDB
$777M
$2.68M 0.63%
472,995
-852,070
-64% -$7.63M
CATX icon
42
Perspective Therapeutics
CATX
$322M
$2.59M 0.61%
260,009
-550,802
-68% -$7.96M
CERS icon
43
Cerus
CERS
$615M
$2.58M 0.61%
1,465,744
– –
CGEN icon
44
Compugen
CGEN
$225M
$2.52M 0.6%
1,501,113
+501,113
+50% +$1.04M
TRVI icon
45
Trevi Therapeutics
TRVI
$2.57B
$2.52M 0.59%
844,235
– –
KOD icon
46
Kodiak Sciences
KOD
$2.62B
$2.5M 0.59%
1,062,062
-176,760
-14% -$599K
JSPR icon
47
Jasper Therapeutics
JSPR
$23.1M
$2.49M 0.59%
109,892
– –
ENGN icon
48
enGene Therapeutics
ENGN
$118M
$2.49M 0.59%
+263,841
New +$3.38M
WVE icon
49
Wave Life Sciences
WVE
$1.14B
$2.47M 0.58%
495,471
– –
FULC icon
50
Fulcrum Therapeutics
FULC
$249M
$2.47M 0.58%
398,436
– –
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Silverarc Capital Management held 91 positions worth $424M, up 18% from $360M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $75.3M of net new capital in Q2 2024, opening 14 new positions and adding to 28 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Perspective Therapeutics, an estimated $7.96M trimmed.

  • Silverarc Capital Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 370,000 shares worth $7.6M.
  • Silverarc Capital Management added most to Nuvalent in Q2 2024, an estimated $21.9M increase.
  • Silverarc Capital Management's biggest Q2 2024 reduction was Perspective Therapeutics, cutting an estimated $7.96M.
  • Silverarc Capital Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $7.89M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $424M portfolio in Q2 2024.
  • Silverarc Capital Management opened 14 new positions and closed 21 in Q2 2024.
  • Silverarc Capital Management's portfolio value rose 18% quarter-over-quarter to $424M.

Based on Silverarc Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.